 |
|
DNA Plasmid Vaccination for Multiple Sclerosis
Olaf Stüve, MD, PhD;
Todd N. Eagar, PhD;
Elliot M. Frohman, MD, PhD;
Petra D. Cravens, PhD
Arch Neurol. 2007;64(10):1385-1386.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In this issue of the Archives, Bar-Or and coworkers1 report on a successful attempt to induce antigen-specific tolerance with a DNA encoding myelin basic protein (MBP) vaccine in patients with multiple sclerosis (MS). Two questions immediately arise: (1) why vaccinate patients with MS with a self antigen, and (2) why use a DNA plasmid vaccine?
Multiple sclerosis is the most common inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system (CNS) in humans. A pathological hallmark of MS is the infiltration of leukocytes into the brain and spinal cord. Not surprisingly, controlling the migration of T cells, B cells, and other immunocompetent myeloid cells into the brain and spinal cord has been a major target of drug development over the last 15 years. Substantial evidence for the role of myelin-specific T . . . [Full Text of this Article] AUTHOR INFORMATION
RELATED ARTICLE
Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial
Amit Bar-Or, Timothy Vollmer, Jack Antel, Douglas L. Arnold, Caroline Anita Bodner, Denise Campagnolo, Jill Gianettoni, Farzaneh Jalili, Norman Kachuck, Yves Lapierre, Masaaki Niino, Joel Oger, Mary Price, Susan Rhodes, William H. Robinson, Fu-Dong Shi, Paul J. Utz, Frank Valone, Leslie Weiner, Lawrence Steinman, and Hideki Garren
Arch Neurol. 2007;64(10):1407-1415.
ABSTRACT
| FULL TEXT
|
